-
Mashup Score: 53Assistant, Associate or Full Professor (HS Clinical, Clinical X, In-Residence, Adjunct) Hematology & Oncology (MED) Faculty - 11 day(s) ago
University of California, San Diego is hiring. Apply now!
Source: apol-recruit.ucsd.eduCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 65
The treatment landscape for metastatic renal cell carcinoma has undergone a fundamental transformation since 2018, transitioning from VEGF-targeted monotherapy to immunotherapy-based combinations. Current treatment decisions are centered on dual immunotherapy (nivolumab plus ipilimumab) or immunotherapy plus VEGF inhibitor combinations. However, long-term data have revealed important nuances in treatment selection, and novel therapeutic strategies are under investigation.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Treatment decisions for frontline RCC getting more complicated with long term data from key landmark studies. We need better (negative selection) biomarkers to choose between IO-IO and IO-VEGF @ASCO https://t.co/CHFmYPaebt
-
-
Mashup Score: 12
PURPOSEThe Brazilian Public Health System (BPHS) serves approximately 71,730 patients with prostate cancer (PC) every year for which androgen deprivation therapy (ADT) is the primary treatment for patients with advanced hormone-sensitive prostate cancer (…
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Amazing work lead by @HerchenhornD demonstrating that surgical castration would allow access to abiraterone to 65%+ Brazilians with mPC without increased cost. @ASCO @JCO_ASCO @Prof_Nick_James @oncodaily https://t.co/ip2yvXD64y
-
-
Mashup Score: 11
PURPOSEThe Brazilian Public Health System (BPHS) serves approximately 71,730 patients with prostate cancer (PC) every year for which androgen deprivation therapy (ADT) is the primary treatment for patients with advanced hormone-sensitive prostate cancer (…
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Amazing work lead by @HerchenhornD demonstrating that surgical castration would allow access to abiraterone to 65%+ Brazilians with mPC without increased cost. @ASCO @JCO_ASCO @Prof_Nick_James @oncodaily https://t.co/ip2yvXD64y
-
-
Mashup Score: 9Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now - PubMed - 8 month(s) ago
Muscle-invasive bladder cancer represents a potentially curable disease, yet often disease recurs and is ultimately fatal. Outcomes for patients with localized urothelial carcinoma are heterogeneous with some patients cured with surgery alone, deriving no benefit from perioperative systemic therapy …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet-
The perioperative use of ctDNA has the potential to transform our approach in localized prostate cancer. This elegant review led by @DrTylerStewart highlights the nuts and bolts. @MattGalsky @apolo_andrea @oncodaily https://t.co/cr6MSuEeaN
-
-
Mashup Score: 29UC San Diego Prostate Cancer Patient Summit - 8 month(s) ago
prostate cancer patient summit
Source: na.eventscloud.comCategories: General Medicine News, Partners & KOLsTweet-
Register for the 3rd Annual Prostate Cancer Patient Summit hosted by @UCSDCancer @PCFnews https://t.co/ww5REPf9tl on 1/31/2025-2/1/2025 at UCSD Park and Market. https://t.co/DVpwXs663b
-
-
Mashup Score: 27Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer | JCO Precision Oncology - 8 month(s) ago
PURPOSEThe acid phosphatase 1 (ACP1) gene encodes low-molecular-weight protein tyrosine phosphatase, which is overexpressed in prostate cancer (PC) and a potential therapeutic target. We analyzed ACP1 expression in primary/metastatic PC and its …High ACP1 expression in prostate cancer is tied to poor outcomes, with potential for targeted therapy
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
So proud of @NourAbdalllah for leading this work in @JCOPO_ASCO evaluating ACP1 expression in PCa. We show enrichment in distant mets, increased TP53 alternations and cold TME. @DrChoueiri @oncodaily @montypal https://t.co/n1QKie7M1R
-
-
Mashup Score: 16UC San Diego Prostate Cancer Patient Summit - 8 month(s) ago
prostate cancer patient summit
Source: na.eventscloud.comCategories: General Medicine News, Partners & KOLsTweet-
Register for the 3rd Annual Prostate Cancer Patient Summit hosted by @UCSDCancer @PCFnews https://t.co/ww5REPf9tl on 1/31/2025-2/1/2025 at UCSD Park and Market. https://t.co/DVpwXs663b
-
-
Mashup Score: 11Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series. - 9 month(s) ago
Advanced prostate cancer treatment has improved with androgen receptor signaling inhibitors (ARPI), yet many patients develop metastatic castration-resistant prostate cancer (mCRPC), characterized by sustained androgen receptor (AR) signaling.
Source: www.urotoday.comCategories: General Medicine News, Partners & KOLsTweet-
Bryce Olson was a remarkable human full of life and resilience. He pushed us all to challenge the status quo. He continues to make an impact in the lives of many. This case report is dedicated to his legacy. @urotoday @OncoAlert https://t.co/LliFirHYl0
-
-
Mashup Score: 5
El Centro Mayor, Sylvia Marroquin, shares her journey with kidney cancer and how a clinical trial at UC San Diego Health saved her life.
Source: today.ucsd.eduCategories: General Medicine News, Partners & KOLsTweet-
Amazing story of hope and resilience from Mayor Marroquin. Clinical trials save lives! @UCSDCancer @ALLIANCE_org @DrChoueiri @TiansterZhang https://t.co/2rJEgT5CIa
-
UCSD GU Medical Oncology is looking for the next academic medical oncologist to join our group! Amazing to see this program continue to blossom. The sky is the limit! @DrChoueiri @neerajaiims @urotoday @OncoAlert https://t.co/KAi2ZtIYjR